๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials in this register

19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of CM383 in Healthy Subjects
NCT07292688Healthy
Keymed Biosciences Co.Ltd
Phase 1
30
Hangzhou
2026-01
Not yet open
Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome
NCT07334873ARDS (Moderate or Severe)
Nanfang Hospital, Southern Medical University
Not applicable
536
Guangzhou
2026-01
Not yet open
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
NCT07277777Malignant Tumors
Li Min
Phase 2
90
Jinan
2026-01
Not yet open
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
NCT07355855Rhabdomyosarcoma
Fudan University
Phase 2
106
Shanghai
2026-01
Not yet open
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
NCT07311863Retinitis Pigmentosa (RP)
Suzhou UgeneX Therapeutics Co., Ltd.
Phase EARLY_PHASE1
6
Shanghai
2026-01
Not yet open
Optimizing Pulp Management in Autotransplantation of Mature Third Molars: A Randomized Controlled Trial
NCT07291531Tooth Avulsion, Dental Pulp Diseases, Tooth, Impacted
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
360
Hangzhou
2026-01
Not yet open
Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)
NCT07332494Coronary Heart Disease, Percutaneous Coronary Intervention
Beijing Anzhen Hospital
Not applicable
792
Beijing, Dalian, Jilin City
2026-01
Not yet open
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
NCT07294300Relapsed/Refractory Hematological Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1
124
Shanghai
2026-01
Not yet open
Aerosolized Mesenchymal Stem Cell-Derived Exosomes for the Prevention and Treatment of Radiation-Induced Oral Mucositis
NCT07312656Oral Mucositis (Ulcerative) Due to Radiation
First Affiliated Hospital of Guangxi Medical University
Phase 2
200
Nanning
2026-01
Not yet open
Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhythmia
NCT07067372Rapid Arrhythmia, PFA, Symptomatic Supraventricular Tachycardia
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Shanghai
2025-12-31
Recruiting
Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
NCT07253129Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
88
Shanghai
2025-12-31
Not yet open
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
NCT07168291Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1
3
Xi'an
2025-12-31
Not yet open
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
NCT07350824HCC, Minimal Residual Disease, Recurrence
Tongji Hospital
Not applicable
276
Wuhan
2025-12-31
Not yet open
Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery
NCT06728605Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute
Nanjing Medical University
Not applicable
400
Nanjing
2025-12-31
Recruiting
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
NCT06981637Advanced Soft Tissue Sarcoma
National Health Research Institutes, Taiwan
Phase 2
81
2025-12-31
Recruiting
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
NCT07330934Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
403
Beijing
2025-12-31
Recruiting
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
NCT07240896Wilsons Disease
DSciLab Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2025-12-31
Not yet open
Assessment of A Novel Emergency Transport Ventilator in Mechanically Ventilated Patients
NCT07198269Patients Receiving Invasive Mechanical Ventilation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
98
Hangzhou
2025-12-31
Not yet open
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
NCT07286695Metastatic Colorectal Cancer (CRC), Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
292
Beijing
2025-12-31
Recruiting
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
NCT07309952Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Yang Hong
Phase 2
28
Guangzhou
2025-12-31
Active, closed
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
NCT07311226Healthy Participants
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
32
Shanghai
2025-12-31
Recruiting
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
NCT07289763Primary Membranous Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
75
Nanjing
2025-12-31
Not yet open
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT07345741R/R B-NHL, Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)
Donghua Zhang
Not applicable
28
Wuhan
2025-12-31
Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction
NCT07304674Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI), Dementia
Xinjiang Medical University
Observational
1,000
Chengdu, รœrรผmqi
2025-12-31
Recruiting
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
NCT07401537Triple -Negative Breast Cancer, Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
416
Guangzhou
2025-12-31
Not yet open
A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects
NCT07334262Food Effect, Mass Balance
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1
24
Shanghai
2025-12-31
Active, closed
An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
NCT06501976Small Cell Lung Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
9
Beijing
2025-12-31
Recruiting
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
NCT07318103Fluid Retention Caused by Heart Failure
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
153
Beijing
2025-12-31
Recruiting
Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis
NCT07360808Systemic Sclerosis (SSc), Hand Dysfunction
Cytori Therapeutics
Not applicable
48
Guangzhou, Shanghai
2025-12-31
Not yet open
Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing
NCT07290816Intestinal Polyps
Shanghai East Hospital
Not applicable
270
Shanghai
2025-12-31
Not yet open
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
NCT07242274NSCLC (Non-small Cell Lung Cancer)
Jemincare
Phase 3
472
Beijing
2025-12-31
Recruiting
A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR
NCT06712862Ischemic Heart Disease
Shanghai East Hospital
Observational
100
Shanghai
2025-12-31
Recruiting
Investigation on Suicide Risk Factors of Patients With Mood Disorders
NCT07523490Mood Disorders, Suicide
Tianjin Anding Hospital
Observational
300
Tianjin
2025-12-31
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Not yet open
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
NCT07324876RCC
Tianjin Medical University Cancer Institute and Hospital
Observational
860
Tianjin
2025-12-31
Recruiting
A Study of B2065 in Patients With Acute Ischemic Stroke
NCT07371624Acute Ischemic Stroke
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2
54
Beijing
2025-12-31
Recruiting
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
NCT07312214Pathologic Myopia
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
158
Shanghai
2025-12-31
Not yet open
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
NCT07264894Mantle Cell Lymphoma (MCL)
Zhengzhou University
Phase 4
30
Zhengzhou
2025-12-31
Recruiting
Study of ZGGS34 in Participants With Advanced Solid Tumors
NCT07258121Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
400
Zhengzhou
2025-12-31
Not yet open
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
NCT07350070HCC, Liver Cirrhosis, Portal Hypertension
Tongji Hospital
Phase 2
78
Fuzhou, Nanning, Taihe, Wuhan, Jinan, Qingdao
2025-12-31
Recruiting
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
NCT07203144Depression - Major Depressive Disorder
First Affiliated Hospital of Chongqing Medical University
Phase 2
172
Chongqing
2025-12-31
Not yet open
The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD)
NCT07315399OSA - Obstructive Sleep Apnea, Coronary Microvascular Dysfunction (CMD), Coronary Artery Disease (CAD)
Beijing Anzhen Hospital
Observational
560
Beijing
2025-12-30
Not yet open
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
NCT07298590IgG4 Related Disease
Changhai Hospital
Phase EARLY_PHASE1
18
Shanghai
2025-12-30
Not yet open
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
NCT07354828Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
Shenyang Northern Hospital
Observational
3,500
Shenyang
2025-12-30
Recruiting
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
NCT07310095Crohn Disease
Xian-Janssen Pharmaceutical Ltd.
Phase 4
78
Guangzhou, Hangzhou, Hefei, Shanghai
2025-12-30
Not yet open
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
NCT07326878Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 1
144
Chongqing
2025-12-30
Not yet open
Prospective, Multicenter, Single-Arm, Phase โ…ก Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
NCT07314619Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University
Phase 2
30
Zhengzhou
2025-12-30
Not yet open
Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
NCT07276854Gastric Cancer, Molecular Imaging
Nanfang Hospital, Southern Medical University
Observational
32
Guangzhou
2025-12-30
Not yet open
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
NCT07318649Locally Advanced or Metastatic Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
Phase 2
120
Hangzhou
2025-12-30
Recruiting
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
NCT07302854Acute Ischemic Stroke, Medium Vessel Occlusion
Xiang Luo
Phase 2/3
382
Wuhan
2025-12-30
Recruiting
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
NCT07362459Non-Small Cell Lung Carcinoma (NSCLC)
Sinocelltech Ltd.
Phase 3
246
Shanghai
2025-12-30
Not yet open
Effect of Different Oxygen Concentrations Before Extubation After General Anesthesia on Hypoxemia After Extubation in Post-anesthesia Care Unit
NCT07293286Hypoxemia
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
590
Guangzhou
2025-12-30
Not yet open
Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhinitis: A Multicenter, Randomized, Double-blind, Controlled Trial
NCT07269509Allergic Rhinitis
Renmin Hospital of Wuhan University
Not applicable
276
Wuhan
2025-12-30
Not yet open
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
HC Biopharma Inc.
Phase 1
32
Beijing
2025-12-30
Recruiting
Web-based Platform for Nutrition Management in Patients With Cancer
NCT07307404Nutrition
Xingchen Peng
Not applicable
84
Chengdu
2025-12-30
Not yet open
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
NCT07257380Gastric / Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
Phase 2
90
Shanghai
2025-12-30
Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
NCT07321574SCLC, Extensive Stage, Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
NCT07309393Residual Neuromuscular Block
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
240
Shanghai
2025-12-30
Not yet open
Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis
NCT07152860Chronic Atrophic Gastritis
Yi Liang
Not applicable
100
Hangzhou
2025-12-30
Not yet open
Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes
NCT07289880Prediabetes
The First Affiliated Hospital of Guangdong Pharmaceutical University
Not applicable
40
Guangzhou
2025-12-30
Recruiting
Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery
NCT07361822Surgery, Pain Management, Opioid Consumption, Patient-controlled Analgesia
Beijing Tiantan Hospital
Not applicable
1,170
Beijing
2025-12-30
Recruiting
Comparison of the Efficacy and Safety of Fixed-rate Basal Infusion Mode and Time-programmed Decremental Background Infusion Mode of Intravenous PCA Following Mixed Surgery
NCT07375121Surgery, Pain Management, Opioid Consumption, Patient Controlled Analgesia
Beijing Tiantan Hospital
Not applicable
450
Beijing
2025-12-30
Not yet open
Randomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation
NCT07243158Mitral Regurgitation Functional
Hangzhou Valgen Medtech Co., Ltd
Not applicable
148
Hangzhou
2025-12-30
Recruiting
Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne
NCT07366229Acne
Shenzhen People's Hospital
Phase 2
196
Shenzhen
2025-12-30
Recruiting
A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
NCT07361237NSCLC (Advanced Non-small Cell Lung Cancer)
Tongji University
Phase 1
36
Shanghai
2025-12-30
Not yet open
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenstrรถm Macroglobulinemia
NCT07259122Waldenstrรถm Macroglobulinemia (WM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
43
Tianjin
2025-12-30
Not yet open
Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
NCT07286110Moyamoya Disease, Moyamoya Syndrome
Fudan University
Phase 1
66
Shanghai
2025-12-30
Recruiting
Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)
NCT07307066ARDS (Acute Respiratory Distress Syndrome), VILI (Ventilator-induced Lung Injury), Respiratory Failure, Critical Illness
Peking Union Medical College Hospital
Not applicable
208
Qujing
2025-12-30
Not yet open
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
NCT07320326TCE-RRMM
Peking University People's Hospital
Observational
159
Beijing
2025-12-30
Recruiting
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
NCT07154082Hepatocellular Carcinoma (HCC)
Wei Zhang
Phase 2
27
Wuhan
2025-12-30
Recruiting
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
NCT07509086Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
The First Hospital of Jilin University
Phase 2
25
Changchun
2025-12-29
Not yet open
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
NCT07277842Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
Sun Yat-sen University
Phase 3
382
Guangzhou
2025-12-29
Recruiting
A Phase II Study of 9MW3811 in Patients With Pathological Scar
NCT07576608Scar
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
30
Shanghai
2025-12-29
By invitation
Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial.
NCT07320937CFS
ShuGuang Hospital
Not applicable
80
Shanghai
2025-12-29
Recruiting
Pilot Trial of Colchicine for Graft Failure in CABG
NCT06802926CABG, Graft Failure, Colchicine
Ruijin Hospital
Phase 4
100
Shanghai
2025-12-29
Recruiting
A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke
NCT07419997Stroke
Xuanwu Hospital, Beijing
Observational
2,600
Beijing
2025-12-29
Recruiting
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
180
Hangzhou
2025-12-29
Recruiting
Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study
NCT07289711Acute Respiratory Distress Syndrome
Southeast University, China
Observational
500
Nanjing
2025-12-29
Recruiting
Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss
NCT07325370Recurrent Pregnancy Loss, Anxiety
Shenyang Medical College
Not applicable
62
Shenyang
2025-12-29
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07297329Multiple Myeloma (MM)
Sinocelltech Ltd.
Phase 3
292
Beijing
2025-12-29
By invitation
Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT07539662ALS (Amyotrophic Lateral Sclerosis)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
8
Tianjin
2025-12-29
Recruiting
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07376642Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1
30
Beijing, Zhengzhou, Hangzhou
2025-12-29
Not yet open
Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture
NCT07279220Femoral Artery Puncture, Vascular Closure Device, Hemostasis
Shanghai Bomaian Medical Technology Co., Ltd
Not applicable
238
Chongqing
2025-12-29
Recruiting
Early Warning and Stratified Diagnosis of Postoperative Respiratory Failure Based on Ventilator Waveform Image Features
NCT07799636Postoperative Respiratory Failure
West China Hospital
Observational
250
Chengdu
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4
NCT07241169Stargardt
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase EARLY_PHASE1
9
Beijing, Guangzhou
2025-12-29
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Beijing, Changsha, Shanghai, Wuhan
2025-12-29
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
NCT07274813Advanced/Metastatic Solid Tumors, NSCLC
Shanghai Henlius Biotech
Phase EARLY_PHASE1
254
Shanghai, Xi'an
2025-12-29
Not yet open
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
NCT07352007HCC
Lei ZHAO
Phase 2
110
Jinan
2025-12-28
Recruiting
The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy
NCT07389083Hypoxia, Pulmonary Nodule, Pulmonary Infection
First Affiliated Hospital of Zhejiang University
Not applicable
50
Hangzhou
2025-12-28
Recruiting
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
NCT07610616HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease
Observational
10
Guangzhou
2025-12-28
Recruiting
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
NCT07680257CLDN18.2 Positive Solid Tumors
Celest Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2025-12-27
Recruiting
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
NCT07195825PD
Shanghai Xinzhi BioMed Co., Ltd.
Phase 1
18
Shanghai
2025-12-27
Not yet open
Cetuximab ฮฒ Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
NCT07327411Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2025-12-27
Recruiting
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
NCT07138547Lymphoma
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2025-12-26
Active, closed
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
NCT07791537Overweight , Obesity
Shanghai Minwei Biotechnology Co., Ltd
Phase 2
125
Luoyang
2025-12-26
Recruiting
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
NCT07326137Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain
Tongji Hospital
Observational
103
Wuhan
2025-12-26
Recruiting
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
NCT07310134Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1
80
Shanghai
2025-12-26
Recruiting
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
NCT07265349Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2
51
Shanghai
2025-12-26
Rows per page Showing 4601–4700 of 19052
Previous 45 46 47 48 49 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china?page=47

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,786 of the 19,052 studies in this register are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3,920 have not yet opened recruitment, 2,668 are active but closed to new participants, and 678 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.